Novartis just swallowed Regulus whole for its kidney drug. 🧪 That's the only story here. The stock spiked on the buyout news, and with the deal basically done, the technicals are irrelevant. The party's over for new investors. It's a SELL if you're in for a trade, as the upside is capped. Time to find the next target. #MergerArb

**Analysis:** Regulus Therapeutics (RGLS) is on a **rocket ride** 🚀, with the stock surging from ~$2.76 to $7.89 in days, fueled by Novartis' acquisition news. The **9-day EMA** ($3.76) just crossed above the **21-day EMA** ($2.78), signaling strong bullish momentum. **RSI is screaming overbought at 96.7** 📈—caution ahead! Volume spiked to **25.4M shares** on the rally, confirming heavy institutional interest. Given the M&A frenzy, this looks like a **"hold for deal close"** play, but don’t chase—RSI suggests a pullback could come soon. 🎢

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Regulus Therapeutics Inc. RGLS: 8.16 USD

Bullish views

Bearish views